Gross Profit Trends Compared: Teva Pharmaceutical Industries Limited vs Catalent, Inc.

Teva vs. Catalent: A Decade of Gross Profit Trends

__timestampCatalent, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 201459860000011056000000
Thursday, January 1, 201561530000011356000000
Friday, January 1, 201658760000011859000000
Sunday, January 1, 201765460000010825000000
Monday, January 1, 20187526000008296000000
Tuesday, January 1, 20198051000007536000000
Wednesday, January 1, 20209833000007725000000
Friday, January 1, 202113520000007594000000
Saturday, January 1, 202216400000006973000000
Sunday, January 1, 202310600000007646000000
Monday, January 1, 20249530000008064000000
Loading chart...

Unveiling the hidden dimensions of data

Gross Profit Trends: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, Teva Pharmaceutical Industries Limited and Catalent, Inc. have showcased intriguing gross profit trends over the past decade. From 2014 to 2023, Teva's gross profit has seen a decline of approximately 31%, dropping from its peak in 2016. This trend reflects the challenges faced by the company in maintaining its market position. In contrast, Catalent has experienced a robust growth trajectory, with its gross profit more than doubling, peaking in 2022. This growth underscores Catalent's strategic advancements and market adaptability. The data for 2024 is incomplete, highlighting the dynamic nature of the industry. These trends offer a snapshot of how strategic decisions and market conditions can significantly impact financial outcomes in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025